Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 3
1988 5
1989 5
1990 5
1991 7
1992 7
1993 7
1994 5
1995 10
1996 11
1997 7
1998 4
1999 5
2000 2
2001 3
2002 4
2003 2
2004 5
2005 7
2006 3
2007 2
2008 1
2010 5
2011 5
2012 4
2013 4
2014 2
2015 2
2016 4
2017 4
2018 3
2019 8
2020 4
2021 9
2022 11
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

171 results
Results by year
Filters applied: . Clear all
Page 1
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S, Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group. Chan A, et al. Among authors: mansi j. Clin Breast Cancer. 2021 Feb;21(1):80-91.e7. doi: 10.1016/j.clbc.2020.09.014. Epub 2020 Oct 6. Clin Breast Cancer. 2021. PMID: 33183970 Free article. Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Among authors: mansi j. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SKL, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group. Chan A, et al. Among authors: mansi j. Lancet Oncol. 2016 Mar;17(3):367-377. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10. Lancet Oncol. 2016. PMID: 26874901 Clinical Trial.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. Earl HM, et al. Among authors: mansi j. Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178152 Free PMC article. Clinical Trial.
Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK.
Earl HM, Hiller L, Dunn J, Macpherson I, Rea D, Hughes-Davies L, McAdam K, Hall P, Mansi J, Wheatley D, Abraham JE, Caldas C, Gasson S, O'Riordan E, Wilcox M, Miles D, Cameron DA, Wardley A. Earl HM, et al. Among authors: mansi j. Clin Oncol (R Coll Radiol). 2021 Jan;33(1):15-19. doi: 10.1016/j.clon.2020.07.006. Epub 2020 Jul 25. Clin Oncol (R Coll Radiol). 2021. PMID: 32723485 Free PMC article. No abstract available.
New drugs. The anthrapyrazoles.
Gogas H, Mansi JL. Gogas H, et al. Among authors: mansi jl. Cancer Treat Rev. 1996 Nov;21(6):541-52. doi: 10.1016/0305-7372(95)90017-9. Cancer Treat Rev. 1996. PMID: 8599804 Review. No abstract available.
Adjuvant chemotherapy for colorectal cancer.
Rayter Z, Leicester RJ, Mansi JL. Rayter Z, et al. Among authors: mansi jl. Ann R Coll Surg Engl. 1995 Mar;77(2):81-4. Ann R Coll Surg Engl. 1995. PMID: 7793820 Free PMC article. Review.
Endometrial stromal sarcomas.
Mansi JL, Ramachandra S, Wiltshaw E, Fisher C. Mansi JL, et al. Gynecol Oncol. 1990 Jan;36(1):113-8. doi: 10.1016/0090-8258(90)90120-a. Gynecol Oncol. 1990. PMID: 2295442
Vaccination against herpes zoster in developed countries: state of the evidence.
Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Drolet M, et al. Among authors: mansi ja. Hum Vaccin Immunother. 2013 May;9(5):1177-84. doi: 10.4161/hv.23491. Epub 2013 Jan 16. Hum Vaccin Immunother. 2013. PMID: 23324598 Free PMC article. Review.
171 results